Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia

被引:45
|
作者
Persson, L [1 ]
Söderquist, B
Engervall, P
Vikerfors, T
Hansson, LO
Tidefelt, U
机构
[1] Orebro Univ Hosp, Dept Infect Dis, SE-70185 Orebro, Sweden
[2] Karolinska Inst, SE-70185 Orebro, Sweden
[3] Orebro Univ Hosp, Dept Clin Microbiol, SE-70185 Orebro, Sweden
[4] Karolinska Univ Hosp Solna, Dept Med, Div Haematol, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Uppsala Hosp, Dept Med Sci Clin Chem & Pharmacol, Uppsala, Sweden
[7] Orebro Univ Hosp, Dept Clin Med, Div Haematol, SE-70185 Orebro, Sweden
关键词
neutropenia; fever; inflammation mediators; SIRS; sepsis;
D O I
10.1111/j.1600-0609.2004.00387.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this study, we evaluated the predictive values of procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6) and serum amyloid A (SAA) for determining the clinical course in febrile neutropenic patients. Daily plasma analyses during the fever course were performed in 101 episodes with fever and chemotherapy-induced neutropenia (neutrophil count < 0.5 x 10(9)/L). Procalcitonin (PCT) and IL-6 values were significantly higher in febrile episodes in patients who developed complications. Procalcitonin with a cut-off value of <= 0.4 ng/mL or IL-6 <= 50 pg/mL 3 d after fever onset indicated daily high negative predictive values (NPVs) (91-100%) for episodes with complications. No marker could predict deterioration; however, daily low plasma concentrations of PCT or IL-6 during the first 8 d of fever were found to be a good predictor of no subsequent complications in neutropenic patients and therefore to be a helpful tool for limiting anti-microbial therapy.
引用
收藏
页码:297 / 303
页数:7
相关论文
共 50 条
  • [1] Role of procalcitonin and CRP in differentiating a stcable from a deteriorating clinical course in pediatric febrile neutropenia
    Secmeer, Gulten
    Devrim, Ilker
    Kara, Ates
    Ceyhan, Mehmet
    Cengiz, Bulent
    Kutluk, Tezer
    Buyukpamukcu, Munevver
    Yetgin, Sevgi
    Tuncer, Murat
    Uludag, Ali Kerem
    Tezer, Hasan
    Yildirim, Inci
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (02) : 107 - 111
  • [2] Pretherapeutic inflammation markers and scores predict febrile neutropenia in SCLC patients
    Kauffmann-Guerrero, D.
    Kahnert, K.
    Syunyaeva, Z.
    Tufman, A.
    Huber, R. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 107 - 107
  • [3] Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study
    Carmona-Bayonas, Alberto
    Jimenez-Fonseca, Paula
    Virizuela Echaburu, Juan
    Antonio, Maite
    Font, Carme
    Biosca, Merce
    Ramchandani, Avinash
    Martinez, Jeronimo
    Hernando Cubero, Jorge
    Espinosa, Javier
    Martinez de Castro, Eva
    Ghanem, Ismael
    Beato, Carmen
    Blasco, Ana
    Garrido, Marcelo
    Bonilla, Yaiza
    Mondejar, Rebeca
    Arcusa Lanza, Maria Angeles
    Aragon Manrique, Isabel
    Manzano, Aranzazu
    Sevillano, Elena
    Castanon, Eduardo
    Cardona, Merce
    Gallardo Martin, Elena
    Perez Armillas, Quionia
    Sanchez Lasheras, Fernando
    Ayala de la Pena, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : 465 - U124
  • [4] Management of Febrile Neutropenia and Application of the Clinical Index for Stable Febrile Neutropenia Tool in a Retrospective Cohort of Breast Cancer Patients
    Guirguis, M.
    Luu, J.
    Bugaj, V
    Bedi, D.
    Elfahl, T.
    Rico, R.
    DeAngelis, C.
    Peragine, C.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2021, 74 (02): : 175 - 175
  • [5] Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients
    Monuszko, Karen A.
    Albright, Benjamin
    De Oca, Mary Katherine Montes
    Nguyen Thao Thi Nguyen
    Havrilesky, Laura J.
    Davidson, Brittany A.
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 37
  • [6] Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy
    Dompeling, EC
    Donnelly, JP
    Raemaekers, JMM
    Deresinski, SC
    Feld, R
    De Pauw, BE
    INFECTION, 1998, 26 (06) : 349 - 354
  • [7] Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy
    E. C. Dompeling
    J. P. Donnelly
    J. M. M. Raemaekers
    S. C. Deresinski
    R. Feld
    B. E. De Pauw
    Infection, 1998, 26 : 349 - 354
  • [8] A retrospective analysis of clinical acuity markers on hospital length of stay in patients with febrile neutropenia
    Johannesmeyer, Herman J.
    Seifert, Charles F.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 535 - 543
  • [9] Febrile neutropenia risk assessment tool: Improving clinical outcomes for oncology patients
    O'Brien, Catherine
    Dempsey, Orla
    Kennedy, M. John
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 (02) : 167 - 174
  • [10] Assessment and comparison of CISNE model versus MASCC model in clinically stable febrile neutropenia patients
    Koppaka, D.
    Kuntegowdanahalli, L. C.
    Lokanath, D.
    Babu, K. Govind
    Jacob, L. A.
    Babu, M. C. Suresh
    Lokesh, K. N.
    Rudresha, A. H.
    Rajeev, L. K.
    Smitha, S. C.
    Anand, A.
    Asati, V.
    Chethan, R.
    Patidar, R.
    Chaudhuri, T.
    Kasturi, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 129 - 129